SYRE Spyre Therapeutics, Inc.
Healthcare$73.65-0.54%ClosedMarket Cap: $4.45B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
38.20
P/S
49.43
EV/EBITDA
-21.74
DCF Value
$0.23
FCF Yield
-4.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
-256.0%
Net Margin
-198.3%
ROE
-31.2%
ROA
-23.5%
ROIC
-34.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-75.6M | $-69.0M | $— | — |
| Q4 null | $90.5M | 50.0% | $-57.2M | $-62.5M | $— | — |
| FY null | $0.00 | -Infinity% | $-209.6M | $-155.2M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-56.9M | $-11.2M | $— | — |
| Q2 null | $0.00 | NaN% | $-41.9M | $-36.7M | $— | — |
| Q1 null | $0.00 | NaN% | $-53.6M | $-44.8M | $— | — |
| Q4 null | $0.00 | NaN% | $-61.3M | $-56.3M | $— | — |
| FY null | $0.00 | NaN% | $-208.6M | $-208.0M | $— | — |
| Q3 null | $0.00 | NaN% | $-55.4M | $-69.0M | $— | — |
| Q2 null | $0.00 | NaN% | $-44.1M | $-38.8M | $— | — |
| Q1 null | $0.00 | NaN% | $-47.8M | $-43.9M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-45.9M | $-63.2M | $-2.91 | — |